Sanitar Co., Ltd. AI Stock Analysis
Sanitar Co., Ltd. (1817) AI Stock Analysis
Sanitar Co., Ltd.
(TWSE:1817)
Sanitar earns an above-average score driven primarily by its financial strength: an almost debt-free balance sheet, a multi-year high in free cash flow, and high earnings quality. This is reinforced by an appealing valuation — a 7.8x P/E paired with a well-covered 5.6% dividend yield. The score is held back by two factors: a stalled top line with revenue down year over year and both operating and net margins compressing, which pulled earnings and ROE lower; and soft near-term technicals, with the price below its 20- and 50-day averages, a negative MACD, and weak RSI/Stochastic readings. The longer-term trend remains constructive with price above its 100- and 200-day averages, and the very low beta suggests a defensive, income-oriented profile where renewed revenue growth is the key catalyst.
Sanitar Co., Ltd. (1817) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.91B
- Dividend Yield
- 5.54%
- Average Volume (3M)
- 48.31K
- Price to Earnings (P/E)
- 7.9
- Beta (1Y)
- 0.08
- Revenue Growth
- -0.86%
- EPS Growth
- 21.67%
- Country
- TW
- Employees
- 1,143
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
Sanitar Co., Ltd. Business Overview & Revenue Model
Company Description
Sanitar Co., Ltd. is a Taiwanese enterprise dedicated to the production and global distribution of porcelain sanitary items, supplying both local and international markets. The company boasts an extensive inventory of bathroom essentials, which encom...
Sanitar Co., Ltd. Financial Statement Overview
Summary
A financially conservative and highly cash-generative business. The balance sheet is the standout (score 85): debt-to-equity of just 0.08, equity funding ~77% of assets, and minimal refinancing risk, though the large equity cushion dilutes ROE to 11.7% from 14.0%. Cash flow is also strong (score 78): operating cash flow rose to NT$467m and free cash flow to a multi-year high of NT$423m, converting ~91% of net income into cash, albeit with historically volatile year-to-year swings. The weak link is the income statement (score 65): revenue fell to NT$2.62bn from NT$2.79bn, net income dropped ~16% to NT$263m, and operating and net margins compressed to 13.7% and 10.1%. Gross margin resilience at 34.9% suggests the core franchise is intact, but growth has stalled.
Income Statement
65PositiveBalance Sheet
85Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.63B | 2.62B | 2.79B | 2.50B | 2.67B | 2.37B |
| Gross Profit | 925.19M | 913.15M | 989.48M | 857.62M | 919.34M | 797.55M |
| EBITDA | 510.74M | 456.18M | 521.64M | 427.30M | 503.97M | 404.19M |
| Net Income | 364.85M | 263.48M | 315.23M | 235.63M | 290.83M | 221.37M |
Balance Sheet | ||||||
| Total Assets | 3.16B | 2.93B | 2.85B | 2.70B | 2.73B | 2.73B |
| Cash, Cash Equivalents and Short-Term Investments | 871.93M | 672.87M | 479.90M | 410.99M | 317.39M | 332.89M |
| Total Debt | 160.83M | 168.78M | 108.80M | 206.59M | 221.08M | 439.10M |
| Total Liabilities | 793.09M | 637.72M | 560.44M | 656.06M | 703.50M | 926.58M |
| Stockholders Equity | 2.32B | 2.25B | 2.25B | 2.01B | 2.00B | 1.78B |
Cash Flow | ||||||
| Free Cash Flow | 295.86M | 423.11M | 249.91M | 299.36M | 330.95M | 215.58M |
| Operating Cash Flow | 331.88M | 467.28M | 309.29M | 335.22M | 354.16M | 247.54M |
| Investing Cash Flow | -245.24M | -135.51M | -151.09M | -57.24M | -35.97M | -5.42M |
| Financing Cash Flow | -226.47M | -136.63M | -228.60M | -196.27M | -386.13M | -135.36M |
Sanitar Co., Ltd. Peers Comparison
Overall Rating
TW:181771Outperform
TW:134162Neutral
TW:846353Neutral
TW:180642Neutral
TW:847638Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | TWD 2.88B | 7.89 | ― | 5.54% | -0.86% | 21.67% | |
| 62Neutral | TWD 3.05B | 11.73 | ― | 6.93% | 1.01% | 22.95% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | TWD 3.19B | 10.76 | ― | 3.76% | -3.02% | -15.76% | |
| 42Neutral | TWD 2.89B | 46.68 | ― | 2.03% | -17.09% | -51.53% | |
| 38Underperform | TWD 2.94B | 66.02 | ― | 1.13% | -0.58% | -19.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1817 | Sanitar Co., Ltd. | 39.70 | 2.60 | 7.01% | |
| TW:1341 | Fulin Plastic Industry (Cayman) Holding Co., Ltd. | 57.70 | 2.89 | 5.27% | |
| TW:1806 | Champion Building Materials Co., Ltd. | 7.39 | -1.50 | -16.85% | |
| TW:6977 | United Purification Technology Co Ltd | 174.50 | 50.70 | 40.96% | |
| TW:8463 | Ruentex Materials Co Ltd | 21.30 | -3.95 | -15.65% | |
| TW:8476 | Taiwan Environment Scientific Co., Ltd. | 17.70 | -0.15 | -0.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
